Top an­a­lyst says the tem­pest over drug prices will like­ly just die out with­out any ma­jor changes

Leerink’s Ge­of­frey Porges is tak­ing a bull­ish view on large cap bio­phar­ma com­pa­nies’ chances for the rest of the year.

Af­ter watch­ing stocks suf­fer through the dol­drums over the last two years, he cites a se­ries of fac­tors that could make the com­ing months more of a treat than a ter­ror for bio­phar­ma in­vestors. Fi­nan­cial fore­casts have mod­er­at­ed to more achiev­able lev­els and there ap­pears to be a bet­ter chance of some ap­peal­ing, though fair­ly lim­it­ed, beats to Wall Street con­sen­sus num­bers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.